Osteoarthritis
Conditions
Brief summary
Recently, the emergence of biotherapies has allowed the use of intra-articular injections of autologous plasma rich platelet (PRP). Their use is widespread since 2010 and is based on the demonstration that platelets-enriched plasma, by virtue of its growth factors concentration, stimulates in vitro and in vivo cartilage regeneration in preclinical models. Recent literature highlights that these autologous products are very well tolerated by humans. PRP, as an intra-articular injection therapy, seems to be an autologous biological medicine, innovative for cartilage injury reparation and showing good primary results for this indication. Adipose tissue contains stromal-vascular fraction (SVF), in which are located a large proportion of mesenchymal multipotent stem cells (Adipose-derived stem cells, ADSCs) able to differentiate into several cellular lines in vitro and in vivo, including cartilage cells. The association of microfat and PRP is interesting in order to potentiate trophic and regenerative effects on damaged cartilage site. The combination of these two products, respectively rich in autologous multipotent stem cells and growth factors, aims to create an optimal environment for cartilage cells regeneration. Furthermore, microfat semi solid phase is playing the role of a nutritive support matrix which contains and limits the diffusion and resorption of PRP liquid while allowing progressive growth factors release on the injection site. The hypothesis of this project is that standardized injection of an innovative treatment (microfat and autologous PRP) should allow delay the use of invasive surgical therapy in the treatment of wrist osteoarthritis. This minimally invasive treatment could provide a curative second line treatment in case of medical treatment failure.
Detailed description
Material and methods: This research protocol aims to evaluate the safety of intra-articular injection of a mixture of autologous microfat associated with autologous PRP for radiocarpal osteoarthritis resistant to medical treatment. This is a prospective, longitudinal, intrasubject, single-center clinical trial phase I-IIa evaluating the safety and feasibility of this innovative treatment. Twelve patients will receive an intra-articular injection of 4 ml of an homogeneous mixture of autologous PRP (2ml) and microfat (2ml).
Interventions
DRUGinjection of microfat and plasma rich platelet PRP
intra-articular injections
DEVICEMRI
MRI 3T
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and females between 20 and 75 years of age * Symptomatic radio-carpal osteoarthritis diagnosed by arthroscanner resistant to medical treatment and candidate to surgery * BMI ≥ 20 Kg/m² * Written informed consent, signed by patient or legal representative (if patient unable to sign). * HB \> 10g/dl * Negative pregnancy test and efficiency contraception
Exclusion criteria
* \- Thrombocytopenia \< 150 G/L, Thrombocytosis \> 450 G/L, Thrombopathy * TP \< 70%, TCA patient / witness rapport \> 1,20 * Anemia: HB \< 10g/dl * Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA * Treatment by platelet inhibiting agent, aspirin, antivitamin K completed more than 2 weeks before inclusion * Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion * Intra articular injection of corticosteroid or hyaluronic acid completed more than 8 weeks before inclusion * NSAI treatment completed more than 2 weeks before inclusion * Fever or recent disease completed more than 1 month before inclusion * Auto immune disease, Inflammatory or microcrystalline Arthritis, Immune deficit * Infectious disease * MRI contraindication: ocular loose bodies, pace maker, neurostimulator, cochlear implant, vascular clips, metallic cardiac val * Anesthesia or surgery contra indication, iodine allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the safety | 1 MONTH | By the number of Adverse event related to the traitment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of pain | 3 ,6, 12 months | with the Visual Analogue Scale (VAS). |
| Improvement of wrist pain | 3 ,6, 12 months | with DASH scores |
| Improvement of wrist pain and function | 3, 6,12 months | with PWRE scores |
| Improvement of radiocarpal chondral lesions | 12 Months | MRI |
Countries
France
Contacts
STUDY_DIRECTORjean-olivier ARNAUD
Assistance Publique Hopitaux De Marseille
Outcome results
None listed